CREB1 and Parkinson disease: The inclusion of the test medicine FSK in the cAMP/PKA/CREB pathway, as well as its antioxidant, anti-inflammatory and neuromodulatory actions, are all possibilities for the processes that could be responsible for the amelioration of PD-like neuropathological abnormalities.